SynthesisJNCI cancer spectrum2021

Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials.

Johnathan Man et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.